Teva Launches an Authorized Generic of Epiduo Forte Gel in the US
2 December 2021 - - Israeli specialty and generic pharmaceutical company Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) (TASE: TEVA) US-based Teva Pharmaceuticals affiliate has launched an authorized generic of Epiduo Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the United States, the company said.

Adapalene and benzoyl peroxide gel 0.3%/2.5% is a topical prescription medicine used to treat acne vulgaris.

With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market, and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the US Currently, 1 in 11 generic prescriptions dispensed in the US is filled with a Teva generic product.

Epiduo Forte Gel had annual sales of USD 253m in the US, according to IQVIA data, as of September 2021.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) has been developing and.


Related Headlines